The results of a review by the Korea Exchange Business Review Committee will be announced today (26), which discussed whether Kolon Tissuejin, which had been controversial due to the inverted new drug, was delisted.

Based on the discussions, the Committee concluded that Kolon Tissuejin did not meet the listing criteria, and concluded with one of three ways to abolish the listing, give an improvement period, or maintain the listing.

Kolon Tissuejin's minority shareholders hold approximately 60,000 people and a 37% stake.